Long-term pharmacotherapy for obesity in elderly patients: A retrospective evaluation of medical records from a specialized obesity outpatient clinic

Drugs and Aging

Volumn 27, Issue 6, 2010, Pages 497-506

  Horie, Nídia Celeste ^a   Cercato, Cintia ^a   Mancini, Marcio C ^a   Halpern, Alfredo ^a  

^a UNIVERSITY OF SÃO PAULO   (Brazil)

Author keywords

[No Author keywords available]

Indexed keywords

AMFEPRAMONE; ANTIOBESITY AGENT; FENPROPOREX; FLUOXETINE; MAZINDOL; SERTRALINE; SIBUTRAMINE; TETRAHYDROLIPSTATIN; TOPIRAMATE;

AGED; ARTICLE; BIPOLAR DISORDER; BODY HEIGHT; BODY MASS; BODY WEIGHT; CHOLELITHIASIS; CONSULTATION; CONTROLLED STUDY; CORONARY ARTERY DISEASE; DIABETES MELLITUS; DIASTOLIC BLOOD PRESSURE; DRUG TOLERABILITY; DYSLIPIDEMIA; ELDERLY CARE; FEMALE; FOLLOW UP; GASTROESOPHAGEAL REFLUX; GLUCOSE INTOLERANCE; HOSPITAL ADMISSION; HUMAN; HYPERTENSION; HYPOTHYROIDISM; LONG TERM CARE; MAJOR CLINICAL STUDY; MAJOR DEPRESSION; MALE; MEDICAL DOCUMENTATION; MEDICAL RECORD; NEOPLASM; OBESITY; OSTEOARTHRITIS; OSTEOPENIA; OSTEOPOROSIS; OUTPATIENT DEPARTMENT; PRESCRIPTION; PRIORITY JOURNAL; RETROSPECTIVE STUDY; SLEEP APNEA SYNDROME; SYSTOLIC BLOOD PRESSURE; TREATMENT RESPONSE; WEIGHT REDUCTION;

EID: 77953275800     PISSN: 1170229X     EISSN: 11791969     Source Type: Journal    
DOI: 10.2165/11536660-000000000-00000     Document Type: Article

References (36)

1. Cercato C, Mancini MC, Arguello AM, et al. Systemic hypertension, diabetes mellitus, and dyslipidemia in relation to body mass index: evaluation of a Brazilian population. Rev Hosp Clin Fac Med Sao Paulo 2004; 59 (3): 113-118
2. Engeland A, Bjorge T, Selmer RM, et al. Height and body mass index in relation to total mortality. Epidemiology 2003; 14: 293-299
3. Blaum CS, Xue QL, Michelon E, et al. The association between obesity and the frailty syndrome in older women: the Women's Health and Aging Studies. J Am Geriatr Soc 2005; 53: 927-934
4. Hopman WM, Berger C, Joseph L, et al., CaMos Research Group. The association between body mass index and health-related quality of life: data from CaMos, a stratified population study. Qual Life Res 2007; 16 (10): 1595-1603
5. Cabrera MAS, Jacob-Filho W. Obesidade em idosos: prevalencia, distribuição e associação com há bitos e co-morbidades [Obesity in elderly: prevalence, distribution and association with behaviour and co-morbidities]. Arq Bras Endocrinol Metab 2001; 45 (5): 494-501
6. Villareal DT, Apovian CM, Kushner RF, et al. Obesity in older adults: technical review and position statement of the American Society for Nutrition and NAASO, The Obesity Society. Am J Clin Nutr 2005; 82 (5): 923-934
7. FIBGE, Fundação Instituto Brasileiro de Geografia e Estatística. Pesquisa de Orçamentos Familiares (POF) 2002-2003 [online]. Available from URL: http://www. ibge.gov.br/estatistica/populacao/ condicoesdevida/pof/2002 analise/defaulttab.shtm [Accessed 2008 Nov]
8. Wallace JI, Schwartz RS. Involuntary weight loss in elderly outpatients: recognition, etiologies, and treatment. Clin Geriatr Med 1997; 13: 717-735
9. Perissinotto E, Pisent C, Sergi G, et al., ILSA Working Group (Italian Longitudinal Study on Ageing). Anthropometric measurements in the elderly: age and gender differences. Br J Nutr 2002; 87 (2): 177-186
10. Steen B. Body composition and aging. Nut Rev 1988; 46 (2): 18-23
11. Beaufrere B, Morio B. Fat and protein redistribution with aging: metabolic considerations. Eur J Clin Nutr 2000; 54 Suppl.: S48-53
12. Cree MG,Newcomer BR, Katsanos CS, et al. Intramuscular and liver triglycerides are increased in the elderly. J Clin Endocrinol Metab 2004; 89: 3864-3871
13. James WP, Astrup A, Finer N, et al. Effect of sibutramine on weight maintenance after weight loss: a randomised trial. STORM Study Group (Sibutramine Trial of Obesity Reduction and Maintenance). Lancet 2000; 356: 2119-2125
14. Torgerson JS, Hauptman J, Boldrin MN, et al. XENical in the prevention of diabetes in obese subjects (XENDOS) study: a randomized study of orlistat as an adjunct to lifestyle changes for the prevention of type 2 diabetes in obese patients. Diabetes Care 2004; 27 (1): 155-161 (Pubitemid 38196725)
15. Huizinga MM. Weight-loss pharmacotherapy: a brief review. Clin Diabet 2007 Oct; 25: 135-140
16. Mancini MC, Halpern A. Pharmacological treatment of obesity. Arq Bras Endocrinol Metabol 2006; 50 (2): 377-389
17. Li Z, Maglione M, Tu W, et al. Meta-analysis: pharmacologic treatment of obesity. Ann Intern Med 2005; 142: 532-546
18. Hind ID, Mangham JE, Ghani SP, et al. Sibutramine pharmacokinetics in young and elderly healthy subjects. Eur J Clin Pharmacol 1999 Jan; 54 (11): 847-849
19. Torp-Pedersen C, Caterson I, Coutinho W, et al. Cardiovascular responses to weight management and sibutramine in high-risk subjects: an analysis from the SCOUT trial. Eur Heart J 2007 Dec; 28 (23): 2915-2923
20. Giorelli P, Ribas-Filho D, Giorelli S, et al. Efficacy of longterm obesity's treatment with diethylpropion. Rev Nutrolog 2008 Oct; 1 (2): 68-74
21. Cercato C, Roizenblatt VA, Leança CC, et al. A randomized double-blind placebo-controlled study of the long-term efficacy and safety of diethylpropion in the treatment of the obese subjects. Int J Obes (Lond) 2009 Aug; 33 (8): 857-865
22. International Narcotics Control Board. Assessments of annual medical and scientific requirements for substances in schedules II, III and IV of the Convention on Psychotropic Substances of 1971: technical report for 2007. New York: United Nations, 2009
23. Hendricks EJ, Rothman RB, Greenway FL. How physician obesity specialists use drugs to treat obesity. Obesity (Silver Spring) 2009 Sep; 17 (9): 1730-1735
24. Mathys M. Pharmacologic agents for the treatment of obesity. Clin Geriatr Med 2005; 21 (4): 735-746
25. World Health Organization. Obesity: preventing and managing the global epidemic. Report on a WHO consultation on obesity; June 3-5, 1997; Geneva, Switzerland [WHO/NUT/NCD/98.1]. Geneva: WHO, 1998
26. Bray GA. Risks of obesity. Prim Care 2003 Jun; 30 (2): 281-299
27. Colman E, Katzel LI, Rogus E, et al. Weight loss reduces abdominal fat and improves insulin action in middle-aged and older men with impaired glucose tolerance. Metabolism 1995; 44: 1502-1508
28. Katzel LI, Bleecker ER, Colman EG, et al. Effects of weight loss vs aerobic exercise training on risk factors for coronary disease in healthy, obese, middle aged and older men. JAMA 1995; 274: 1915-1921
29. Kumanyika SK, Espeland MA, Bahnson JL, et al., for the TONE Cooperative Research Group. Ethnic comparison of weight loss in the trial of nonpharmacologic interventions in the elderly. Obes Res 2002; 10: 96-106
30. Womack CJ, Harris DL, Katzel LI, et al. Weight loss, not aerobic exercise, improves pulmonary function in older obese men. J Gerontol A Biol Sci Med Sci 2000; 55 (8): M453-7
31. Felson DT, Zhang Y, Anthony JM, et al. Weight loss reduces the risk for symptomatic knee osteoarthritis in women: the Framingham Study. Ann Intern Med 1992; 116: 535-539
32. ZamboniM,Mazzali G, Zoico E, et al. Health consequences of obesity in the elderly: a review of four unresolved questions. Int J Obes 2005; 29 (9): 1011-1029
33. Chobanian AV, Bakris GL, Black HR, et al., National High Blood Pressure Education Program Coordinating Committee. The seventh report of the JointNational Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure: the JNC 7 report. Hypertension 2003; 42: 1206-1252
34. Frank A. The long-term management of obesity with continuing pharmacotherapy. Obes Res 2004; 12: 1821-1827
35. Agencia Nacional de Vigilancia Sanitá ria (ANVISA) Parecer técnico-cient́fico do Grupo Assessor de Estudos sobre Medicamentos Anorex́genos [Technical and scientific opinion of the Advisory Group for the Study of Anorectic drugs]. Brasilia: Diá rio Oficial da Uniao, 2000 Jul 21
36. Phelan S, Wadden TA. Combining behavioural and pharmacological treatments for obesity. Obes Res 2002; 10: 560-574